论文部分内容阅读
目的:检测上皮性卵巢癌间质及上皮中TGF-β1表达情况,探讨其与肿瘤铂类耐药的相关性。方法:采用免疫组织化学方法检测43例术后应用铂类药物化疗的上皮性卵巢癌标本间质和上皮中TGF-β1的表达水平,并追踪调查12个月,记录肿瘤复发情况。结果:①上皮性卵巢癌中TGF-β1在上皮中表达阳性率为58.1%,间质中为81.4%,具有显著性差异(P=0.028)。②12个月内复发组和未复发组中卵巢癌上皮内TGF-β1的阳性表达率无显著性差异(P=0.594);复发组卵巢癌间质中TGF-β1阳性表达显著高于未复发组(P=0.042)。结论:上皮性卵巢癌间质中TGF-β1表达可能提示该患者对铂类药物具有更高的耐药性。
OBJECTIVE: To detect the expression of TGF-β1 in epithelial ovarian stromal and epithelial epithelial cells and to explore its relationship with platinum resistance. Methods: Immunohistochemical method was used to detect the expression of TGF-β1 in 43 specimens of epithelial ovarian cancer after surgery with platinum-based chemotherapy. The expression of TGF-β1 in the epithelium was detected by immunohistochemistry. The recurrence was recorded after 12 months. RESULTS: ① The positive rate of TGF-β1 in epithelial ovarian carcinoma was 58.1% in epithelial ovarian epithelial cells and 81.4% in interstitial cells, with a significant difference (P = 0.028). ② The positive rate of TGF-β1 expression in ovarian cancer epithelium was not significantly different between recurrence group and non-recurrence group within 12 months (P = 0.594); The positive expression of TGF-β1 in recurrence group was significantly higher than that in non-recurrence group (P = 0.042). CONCLUSIONS: The expression of TGF-β1 in epithelial ovarian cancer stroma may indicate that this patient has higher resistance to platinum drugs.